Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06101095 · ClinicalTrials.gov registry record · Phase 4
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
A Phase 4 study of Eosinophilic Oesophagitis, sponsored by Sanofi.
- Active
- Registry status
- Phase 4
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT06101095 is a Phase 4 study of Eosinophilic Oesophagitis that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 69 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT06101095, a Phase 4 study of Eosinophilic Oesophagitis, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis. Duration of study period (per participant) * Screening period: Up to 12 weeks before Week 0 * Randomized double-blind period: 24 weeks * Open label period: 104 weeks * Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first. There will be ten (10) site visits, and five (5) direct-to-participant IMP delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. In this case, IMP will be dispensed at the study site).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
Study Locations (20)
Illinois
- Northwestern University- Site Number : 8400003 - Chicago
- GI Alliance - Glenview- Site Number : 8400012 - Glenview
- Illinois Gastroenterology Group- Site Number : 8400004 - Gurnee
California
- United Gastroenterologists - Murrieta- Site Number : 8400001 - Murrieta
- University of California San Francisco - Parnassus Heights- Site Number : 8400020 - San Francisco
Texas
- Private Practice - Dr. Martin Yudovich- Site Number : 8400015 - Houston
- GI Alliance - Mansfield- Site Number : 8400017 - Mansfield
São Paulo
- Clínica Loema - Unidade I- Site Number : 0760007 - Campinas
- Clinica de Alergia Martti Antila- Site Number : 0760001 - Sorocaba
Florida
- Borland Groover Clinic- Site Number : 8400016 - Jacksonville
Idaho
- Treasure Valley Medical Research- Site Number : 8400018 - Boise
Iowa
- University of Iowa- Site Number : 8400006 - Iowa City
Massachusetts
- University of Massachusetts Chan Medical School- Site Number : 8400019 - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2023-11-29 |
| Est. Completion | 2028-02-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06101095
The ClinicalTrials.gov registry entry for NCT06101095 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Oesophagitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06101095 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Illinois, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06101095 about?
NCT06101095 is a clinical study titled "A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)". This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal funct...
What is the current status of trial NCT06101095?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2023-11-29. Estimated completion is 2028-02-01.
What conditions does trial NCT06101095 study?
This clinical trial studies the following conditions: Eosinophilic Oesophagitis.
What interventions are being tested in trial NCT06101095?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT06101095?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06101095 being conducted?
This trial has 20 study locations across California, Florida, Idaho, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.